002107.SHE Shandong Wohua Pharmaceutical Co Ltd
- Market cap
- CNY 3.36B
- P/E
- 26.5x
- P/B
- 5.05x
- ROE
- 19.1%
- Dividend yield
- 2.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 002107.SHE undervalued?
Graham number002107.SHE trades 143.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Wohua Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shandong Wohua Pharmaceutical Co Ltd yet.
Shandong Wohua Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Wohua Pharmaceutical Co Ltd
Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and T…
Full company profileShandong Wohua Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Wohua Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 563M | 727M | 774M | 860M | 1.01B | 943M | 1.01B | 910M | 764M | 817M | 787M |
| Gross Profit | 420M | 570M | 596M | 656M | 780M | 728M | 760M | 675M | 553M | 614M | 612M |
| Operating Income | 66.9M | 91.8M | 44.2M | 111M | 223M | 193M | 112M | 56.5M | 44.6M | 104M | 160M |
| EBITDA | 99.6M | 121M | 69.0M | 133M | 255M | 229M | 146M | 87.3M | 74.7M | 133M | 162M |
| Net Income | 48.8M | 57.0M | 45.7M | 95.8M | 179M | 163M | 107M | 58.8M | 36.4M | 95.7M | 135M |
| EPS | 0.09 | 0.10 | 0.08 | 0.17 | 0.31 | 0.28 | 0.19 | 0.10 | 0.06 | 0.17 | 0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 706M | 855M | 922M | 1.01B | 1.37B | 1.16B | 1.10B | 1.14B | 986M | 977M | 956M |
| Total Liabilities | 133M | 200M | 227M | 233M | 452M | 232M | 310M | 311M | 263M | 245M | 251M |
| Shareholders' Equity | 489M | 548M | 594M | 672M | 807M | 821M | 747M | 805M | 697M | 724M | 707M |
| Cash & Short-term Investments | 194M | 305M | 323M | 301M | 494M | 327M | 278M | 401M | 345M | 394M | 386M |
| Total Debt | 30.1M | 27.8M | 1.38M | 1.95M | 189M | 2.83M | 1.41M | 2.73M | 1.15M | 2.86M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 72.9M | 124M | 108M | 31.7M | 197M | 200M | 185M | 129M | 91.5M | 129M | - |
| Capital Expenditure | 27.7M | 15.1M | 63.1M | 32.2M | 54.2M | 19.1M | 6.77M | 2.72M | 3.82M | 865K | 2.19M |
| Free Cash Flow | 45.3M | 109M | 44.8M | -573K | 142M | 181M | 178M | 127M | 87.7M | 128M | 161M |
| Ratios | |||||||||||
| ROE | 10.0% | 10.4% | 7.7% | 14.3% | 22.2% | 19.9% | 14.4% | 7.3% | 5.2% | 13.2% | 19.1% |
| ROA | 6.9% | 6.7% | 4.9% | 9.5% | 13.1% | 14.1% | 9.8% | 5.1% | 3.7% | 9.8% | 14.1% |
| Net Profit Margin | 8.7% | 7.8% | 5.9% | 11.1% | 17.8% | 17.3% | 10.6% | 6.5% | 4.8% | 11.7% | 17.2% |
| Debt to Equity | 0.06x | 0.05x | 0.00x | 0.00x | 0.23x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Wohua Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.06%
- Forward dividend
- 0.26 CNY
- Payout ratio
- 72.4%
- Ex-dividend date
- Aug 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 69.3M | 0.12 | 72.4% |
| 2024 | CNY 144M | 0.24 | 396.4% |
| 2023 | - | - | - |
| 2022 | CNY 150M | 0.27 | 139.8% |
| 2021 | CNY 155M | 0.27 | 94.8% |
| 2020 | CNY 47.8M | 0.08 | 26.7% |
| 2019 | CNY 18.7M | 0.03 | 19.5% |
| 2018 | CNY 18.7M | 0.03 | 40.9% |
| 2017 | CNY 18.7M | 0.03 | 32.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on May 29, 2020.
Who owns Shandong Wohua Pharmaceutical Co Ltd
- Insiders 54.01%
- Institutions 1.06%
- Public & others 44.93%
- Shares outstanding 577M
- Free float 278M
Shandong Wohua Pharmaceutical Co Ltd company profile
- Company name
- Shandong Wohua Pharmaceutical Co Ltd
- Ticker
- 002107.SHE
- ISIN
- CNE000001QB8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jan 24, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,018
- Fiscal year end
- December
- Address
- No. 3517 Liyuan Street, Weifang, China, 261205
- Phone
- 86 53 6855 3373
- Website
- wohua.cn
About Shandong Wohua Pharmaceutical Co Ltd
Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and Tongluo Huatan capsules; and drugs for musculoskeletal disorders, including Gusukang capsules/granules and Yidu Hanbi liquid; Yidu cold-rheumatism medicinal wine ingredients; brain blood circulation oral solution; Amber stone granules for urinary system diseases; Children's antipyretic granules for pediatric medication; Anti-itching granules for skin diseases; and Bile grass capsule for digestive and gynecological diseases, as well as Silkworm Nourishing Blood and Benefiting Kidney Granules for gynecological medication. In addition, the company offers Amber Xiaoshi granules, and Siyu Yangxue Yishen granules; Yanreqing granules, Antiviral oral liquid, and Niuhuang Yijin tablets for the treatment of dry throat and sore throat; Yinhuang granules for the treatment of wind-heat colds; Tongxuan Lifei pills for the treatment of wind-cold colds; Fangfeng Tongsheng pills for colds on the surface and heat inside; Huoxiang Zhengqi Water for the treatment of summer-heat colds; Shenling Baizhu, Buzhong Yiqi, and Xiangsha Liujun pills for the treatment of physical weakness colds; and Juhong Li Gao for the treatment of dry coughs with little sputum. The company was founded in 2003 and is based in Weifang, China. Shandong Wohua Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Zhongzheng Wanrong Investment(Group) Co., Ltd.
Shandong Wohua Pharmaceutical Co Ltd management
5- Mr. Shengting LiPresident · born 1968
- Mr. Jiong WangCFO, Accounting Supervisor & Director · born 1973
- Mr. Ge ZhangDirector & Secretary of The Board · born 1970
- Ms. Yingzi ZengVice President · born 1963
- Ms. Qian YangDeputy General Manager · born 1968